GSK 256073
Alternative Names: 256073; GSK-256073Latest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antihyperlipidaemics
- Mechanism of Action G protein-coupled receptor agonists; GPR109A receptor agonists; Nicotinic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Dyslipidaemias; Type 2 diabetes mellitus
Most Recent Events
- 30 Sep 2011 Phase-II clinical trials in Type-2 diabetes mellitus (adjunctive treatment) in United Kingdom, France and Spain (PO)
- 30 Sep 2011 Phase-II clinical trials in Type-2 diabetes mellitus in USA (PO)
- 06 May 2010 GSK completes a phase II trial in Dyslipidaemia in the US (NCT00903617)